Press Release Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update 6 hours ago
Press Release Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE) 14 hours ago
Press Release Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study’s Pre-Specified Threshold for Success Jul 21